121 related articles for article (PubMed ID: 30288002)
21.
Seo Y; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
J Breast Cancer; 2018 Dec; 21(4):382-390. PubMed ID: 30607159
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
[TBL] [Abstract][Full Text] [Related]
23. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
[TBL] [Abstract][Full Text] [Related]
25. Investigation of somatic PIK3CA gene mutations in breast cancer patients.
M.Pevzner A; A.Gaptulbarova K; M.Tsyganov M; Κ.Ibragimova M; V.Vvedensky A; G.Zhusina Y; V.Pyankov D; A.Korostylev S; V.Litviakov N
J BUON; 2021; 26(3):747-752. PubMed ID: 34268930
[TBL] [Abstract][Full Text] [Related]
26. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P; Karn T; van Mackelenbergh M; Lindner J; Treue D; Huober J; Engels K; Solbach C; Diebold K; Marme F; Müller V; Schneeweiss A; Sinn HP; Fehm T; Schem C; Stickeler E; Fasching PA; Budczies J; Felder B; Nekljudova V; Holtschmidt J; Untch M; Denkert C; Loibl S
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38837894
[TBL] [Abstract][Full Text] [Related]
27. Analysis of PIK3CA mutations in breast cancer subtypes.
Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
[TBL] [Abstract][Full Text] [Related]
28. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
29. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
30. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
31. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
[TBL] [Abstract][Full Text] [Related]
32. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Anderson EJ; Mollon LE; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Int J Breast Cancer; 2020; 2020():3759179. PubMed ID: 32637176
[TBL] [Abstract][Full Text] [Related]
33. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
34. Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
Li H; Xu Y; Zhao F; Song G; Rugo HS; Zhang Y; Yang L; Liu X; Shao B; Yang L; Liu Y; Ran R; Zhang R; Guan Y; Chang L; Yi X
Am J Cancer Res; 2018; 8(9):1873-1886. PubMed ID: 30323979
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
36. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
37. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
39. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
40. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
